Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724841 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
A Phase 1 study, sponsored by Gemin X.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00724841 is a Phase 1 study that was terminated before completion, run by Gemin X. The registered enrollment target is 1 participants.
The verdict
NCT00724841, a Phase 1 study, was terminated before completion, sponsored by Gemin X.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
Interventions
- DRUG Temozolomide
- DRUG Obatoclax Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724841
The ClinicalTrials.gov registry entry for NCT00724841 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gemin X, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT00724841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724841 about?
NCT00724841 is a clinical study titled "A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma". Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
What is the current status of trial NCT00724841?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2008-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00724841?
The interventions under investigation include: Temozolomide (DRUG), Obatoclax Mesylate (DRUG).
Who is sponsoring clinical trial NCT00724841?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.